We're crowdfunding! Own a part of our business. Capital at Risk.
View our pitch
Crowdcube

Pioneering a new era of fridge free vaccines and pharmaceuticals

StablevaX™ platform enables the reformulation of vaccines and pharmaceutical products into thermostable forms that remain safe and effective at temperatures of 40°C and above.

Stablepharma awarded the highly competitive and prestigious EIC Accelerator Grant of €2.5mOur technology platform, StablevaX™ converts existing vaccines and biologicals into thermostable products

The Reality

One of the biggest barriers to global health is the inability to deliver temperature sensitive pharmaceutical products, such as vaccines, whilst having to rely on the global cold chain. The high rate of wastage experienced during distribution and storage further exacerbate this issue. According to the World Health Organisation, over 50% of vaccines are wasted annually, primarily due to failures in the logistical cold chain. CC Challenge graphic  

"Our vision is to save lives and reduce global wastage by making fridge-free vaccines, diagnostics, and pharmaceuticals a reality"

 

Climate change is the biggest health threat we face, with 250,000 additional deaths projected each year. Healthcare generates 4.4% of global CO₂ emissions - more per dollar than the automotive sector. Stablepharma helps reduce these emissions by making vaccine and pharmaceutical products fridge-free, reducing reliance on the energy-intensive refrigerated cold chain.

Stablepharma’s innovative pharmaceutical technology aims to redefine immunisation efforts, boosting access, tackling waste and reducing reliance on the global cold chain. Learn More

Awards & Recognitions

We are proud to be recognized for our innovation and impact in the biotech industry

The pharmaceutical cold chain emits 55% more greenhouse gas emissions than the automotive sector. The pharmaceutical supply chain relies on fossil fuels, from warehousing and storage to transportation and delivery of temperature-sensitive goods.

MENU